SIGA Technologies Inc
$ 4.32
-2.70%
02 Jun - close price
- Market Cap 318,455,000 USD
- Current Price $ 4.32
- High / Low $ 4.46 / 4.28
- Stock P/E 15.86
- Book Value 2.78
- EPS 0.28
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.11 %
- 52 Week High 8.51
- 52 Week Low 4.10
About
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$17.53
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-10 | 2025-11-06 | 2025-08-05 | 2025-05-08 | 2025-03-11 | 2024-11-07 | 2024-08-01 | 2024-05-07 | 2024-03-12 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.0482 | -0.0758 | -0.0889 | 0.49 | -0.0057 | 0.6409 | 0.0187 | 0.0255 | 0.1436 | 1.0164 | -0.01 | -0.04 |
| Estimated EPS | 0 | 0 | 0 | 0 | None | None | None | None | 0.14 | 1.01 | -0.01 | -0.04 |
| Surprise | -0.0482 | -0.0758 | -0.0889 | 0.49 | 0 | 0 | 0 | 0 | 0.0036 | 0.0064 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | 2.5714% | 0.6337% | 0% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Apr 2026 | May 2025 | Apr 2024 | Jun 2023 | Jun 2022 | |
|---|---|---|---|---|---|
| Payment Date | 2026-04-23 | 2025-05-15 | 2024-04-11 | 2023-06-01 | 2022-06-02 |
| Amount | $0.6 | $0.6 | $0.6 | $0.45 | $0.45 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SIGA
2026-05-29 03:38:58
SIGA Technologies, Inc. has announced an agreement to sell its antiviral drug TPOXX (tecovirimat) to member states of the Association of Southeast Asian Nations (ASEAN). This agreement, coordinated with Meridian Medical Technologies, LLC and signed by Brunei Darussalam's Ministry of Health on behalf of ASEAN, aims to strengthen the region's preparedness for potential public health events and expand TPOXX's global access. The deal signifies a strategic step for SIGA into the highly populated Asian market to enhance orthopoxvirus preparedness, though financial terms were not disclosed.
2026-05-15 10:17:00
SIGA Technologies experienced a 9.9% stock drop following a significant Q1 2026 revenue miss and a sharper net loss. The company reported revenue of US$6.24 million, down from US$7.04 million, and a net loss of US$3.45 million, compared to US$0.41 million the previous year. This performance highlights SIGA's vulnerability to inconsistent government contract timing and its impact on profitability and share price, despite management's readiness to return cash via special dividends.
2026-05-14 11:10:17
Despite seemingly soft headline earnings, SIGA Technologies' shareholders may have reason for optimism due to positive underlying factors. The company's accrual ratio of -0.24 indicates that its free cash flow significantly exceeded its statutory profit, suggesting its earnings potential might be understated. While earnings per share fell, the strong conversion of profit to free cash flow is a positive indicator for the company.
2026-05-14 11:09:45
Despite what appears to be lackluster earnings, SIGA Technologies, Inc.'s shareholders might have reasons to be optimistic. The company's strong accrual ratio of -0.24 indicates that its free cash flow significantly exceeded its statutory profit, suggesting that reported profits may actually understate its true earnings potential. This strong cash conversion ability could be a positive underlying factor balancing the softer headline numbers.
2026-05-08 22:09:19
SIGA Technologies reported minimal product deliveries for Q1 2026 but anticipates a $13 million oral TPOXX order from an international customer and additional IV TPOXX deliveries to the Strategic National Stockpile (SNS) in Q2. CEO Diem Nguyen highlighted the company's commitment to global biological threat preparedness, emphasizing TPOXX's suitability for large-scale deployment. The company remains engaged with the U.S. government and expresses confidence in its long-term outlook despite quarterly variability.
2026-05-08 00:09:46
Siga Technologies reported a first-quarter loss due to minimal product deliveries but anticipates an increase in Q2 from an international order and U.S. Strategic National Stockpile deliveries. CEO Diem Nguyen emphasized the company's focus on partnering with governments to address biological threats, particularly smallpox, with TPOXX. The company continues contract discussions with the U.S. government and is expanding international efforts, including a new agreement with Hikma for the Middle East and North Africa region.
